At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of ovarian epithelial, primary peritoneal, or fallopian tube cancer
- ✓Recurrent disease with prior platinum-based regimen
- ✓Platinum-sensitive (treatment-free interval >6 months)
- ✓No more than 2 prior chemotherapy regimens
- ✕Known brain metastases
- ✕Other invasive malignancy within past 5 years (except nonmelanoma skin cancer)
- ✕Symptomatic congestive heart failure
- ✕Uncontrolled hypertension, cardiac arrhythmia, unstable angina, or myocardial infarction within 6 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer
In Brief
A Phase 2 clinical trial evaluating Carboplatin, Paclitaxel, and 1 other intervention for Recurrent Fallopian Tube Carcinoma and 2 related conditions. Completed, enrolled 44 participants across 5 sites.
Detailed Summary
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving sorafenib together with chemotherapy may kill more tumor cells. This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with recurrent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. (Sorafenib only group closed as of 10/10/2008).
Study Details
Timeline
Interventions
Given IV
Given IV
Given orally